NovoCure Limited
NVCR
$12.43
$0.524.37%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 14.58% | 18.27% | 18.82% | 14.63% | 8.33% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 14.58% | 18.27% | 18.82% | 14.63% | 8.33% |
| Cost of Revenue | 11.82% | 7.18% | 6.82% | 9.29% | 8.70% |
| Gross Profit | 15.46% | 21.98% | 22.84% | 16.38% | 8.22% |
| SG&A Expenses | 15.05% | 11.87% | 10.83% | 1.00% | 8.38% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.12% | 7.44% | 5.34% | 0.33% | 4.41% |
| Operating Income | 3.66% | 20.03% | 25.03% | 31.91% | 6.08% |
| Income Before Tax | -0.66% | 24.66% | 31.59% | 38.37% | 12.32% |
| Income Tax Expenses | 4.76% | 68.16% | 144.82% | 206.82% | 105.78% |
| Earnings from Continuing Operations | -1.33% | 14.82% | 18.55% | 24.07% | 3.25% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.33% | 14.82% | 18.55% | 24.07% | 3.25% |
| EBIT | 3.66% | 20.03% | 25.03% | 31.91% | 6.08% |
| EBITDA | 4.49% | 21.32% | 26.23% | 33.24% | 6.51% |
| EPS Basic | 0.87% | 16.28% | 19.77% | 25.11% | 4.62% |
| Normalized Basic EPS | -1.67% | 19.59% | 26.19% | 29.69% | 3.28% |
| EPS Diluted | 0.86% | 16.28% | 19.76% | 25.11% | 4.62% |
| Normalized Diluted EPS | -1.67% | 19.59% | 26.19% | 29.69% | 3.28% |
| Average Basic Shares Outstanding | 2.30% | 1.73% | 1.40% | 1.52% | 1.62% |
| Average Diluted Shares Outstanding | 2.30% | 1.73% | 1.40% | 1.52% | 1.62% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |